Vermox
Studies on anthelmintic effects of flubendazole and mebendazole on the rat lungworm Angiostrongylus cantonensis in mice and rats.

Maki J, Yanagisawa T.

Flubendazole and mebendazole given orally at 10 mg/kg/day 5-7 days post-infection (total 30 mg/kg) were found to eliminate 93-100% of Angiostrongylus cantonensis larvae in mice and rats. No significant difference was observed between the effects of the 2 drugs. The effectiveness of the drugs decreased with the increase in days post-infection on which medication was administered. It was found possible to treat A. cantonensis adults in rats by administering flubendazole or mebendazole at 10 mg/kg/day for 10 consecutive days. The drugs exhibited better anthelmintic efficacy in a divided dosing regimen than in a single dosing regimen.

Online source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=3783345&dopt=Abstract mebendazole Vermox



Vermox
Treatment of hydatid disease with high oral doses of mebendazole. Long-term follow-up of plasma mebendazole levels and drug interactions.

Luder PJ, Siffert B, Witassek F, Meister F, Bircher J.

Plasma mebendazole levels were analysed retrospectively in patients treated for inoperable infections with Echinococcus multilocularis or granulosus. In 10 patients receiving mebendazole at 4 dose levels there was no relation between dose and plasma concentration. In 17 patients followed on the same dose for more than 18 months, the plasma levels varied with individual coefficients of variation ranging from 27 to 72%. The data reveal the limitations of single measurements of plasma mebendazole and emphasize the need for repeated monitoring. Coadministration of phenytoin and carbamazepine seemed to lower plasma levels, presumably as a result of enzyme induction. It was not possible appreciably to raise the mebendazole concentrations by inhibition of drug metabolizing enzymes with cimetidine.

Online source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=3816925&dopt=Abstract mebendazole Vermox



Vermox
Attempts to modify treatment of intestinal capillariasis.

Basaca-Sevilla V, Cross JH.

Attempts to reduce the standard treatment of intestinal capillariasis of 200 mg mebendazole twice daily for 20 days were not successful. Two of 13 patients given mebendazole at single daily dosages of 500 mg per day for 16 days relapsed 3 to 6 months after treatment. Attempts to reduce the treatment to 14 days were even less satisfactory in that 4 of 8 patients treated experienced relapses 2 to 9 months later. Since intestinal capillariasis can be fatal it is recommended to continue the use of the standard schedule of 400 mg mebendazole daily for 20 days for new cases and 30 days for relapsed cases until a more effective drug is available.

Online source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=3835695&dopt=Abstract mebendazole Vermox



Vermox
First experience in the treatment of human hydatid disease with mebendazole.

De Rosa F, Teggi A.

The authors report their experience with mebendazole in human hydatid disease. Following a WHO-controlled protocol, 25 patients with hydatidosis were treated with mebendazole, 50 mg/kg/die for 4-8 months. A further 2 patients were treated with mebendazole 30 mg/kg/die for 6 months, outside the WHO protocol. The evaluation of the results was performed by clinical, radiological (X-ray, ultrasounds, computerized tomography) and immunological investigations (monitoring of indirect haemoagglutinating antibodies, specific IgE, lymphocytic blastization, circulating immune complexes, etc.). The results were encouraging and the side-effects were not important; nevertheless, many questions remain to be elucidated.

Online source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=3836117&dopt=Abstract mebendazole Vermox



Vermox
[Mebendazole treatment of echinococcosis]

[Article in French]

Kern P, Rippmann K, Van Ackeren H, Dietrich M.

Forty patients with echinococcosis were treated with mebendazole (approximately 50 mg/kg body weight) and under observation for up to 8 years. In 8 patients, E. multilocularis-infection was diagnosed whereas 32 patients had liver (n = 19 lung, n = 7) or other infestations of E. granulosus. 23 patients had been treated with mebendazole alone. 20 further patients received the treatment pre- and post-operatively and in the remaining cases mebendazole was given pre- or post-operatively according to the patients' requirements. Besides the clinical and laboratory findings, morphological parameters of organ infestation due to the parasites were examined repeatedly by x-ray, ultra sound, Ct-scan or scintigram. In the course of treatment we noticed that mebendazole had a certain effect in the case of E. multilocularis-infection and in the case of lung infestation due to E. granulosus. Furthermore, patients who were treated with mebendazole and who were under observation for several years, showed improvement of the liver cyst. The analysis of all morphological data available from patients with liver cysts indicated that marked changes had already been observed in the period of one to thirty months after the beginning of therapy.

Online source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=3836757&dopt=Abstract mebendazole Vermox



Vermox
[Filariasis in Gabon: treatment with mebendazole of filariasis due to M. perstans and Loa loa]

[Article in French]

Richard-Lenoble D, Kombila M, Burnier I, Maganga ML.

Mebendazole (Vermox 500) in long duration treatment 2 g/day for 3 to 4 weeks, is sometimes indicated in therapy of Loa Loa filariasis but remains the only active therapy on M. perstans filariasis. The perfect product tolerance and efficacy allow large indication in treatment of this last filariasis, the most often found in Gabon (Central Africa).

Online source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=3865739&dopt=Abstract mebendazole Vermox